{"entity":{"id":"nct06079112","kind":"trial","name":"9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer","aka":[],"tldr":"A phase 1/2 trial of Toripalimab in bladder & urothelial cancer, run by Mabwell (Shanghai) Bioscience Co., Ltd., now recruiting.","summary":"9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer is a phase 1/2 interventional study registered as NCT06079112 by Mabwell (Shanghai) Bioscience Co., Ltd., with 100 participants planned, started 2023-09-27 and due to reach its primary completion in 2026-12-31. Interventions recorded: 9MW2821 and Toripalimab.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06079112","url":"https://clinicaltrials.gov/study/NCT06079112"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["urothelial"],"sections":[],"technologies":[],"targets":[],"drugs":["toripalimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06079112","phase":"1/2","setting":"A Phase Ib/II, Open-label, Single Arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of 9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","enrolled":100,"outcomes":[]},"route":"/trials/nct06079112/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}],"drug":[{"id":"toripalimab","kind":"drug","name":"Toripalimab","route":"/drugs/toripalimab/"}]}}